The president says current subscribers will be able to keep their plans.
Site fixes are reported to lag, but CMS plans on inviting consumers to give Healthcare.gov another go.
Official numbers are pending, but Reuters notes enrollment appears to be just 3% of the government's goal.
The Centers for Medicare and Medicaid Services won't say if the change is connected to Healthcare.gov's bumpy launch.
General support for the legislation is up, despite Healthcare.gov woes.
They're not hiding their love or disdain for reform, including one who says the law brings bias into the exam room.
Subscribers will be able to use co-pay cards on Obamacare exchanges.
Five percent of the patient population accounts for 50% of US healthcare costs, one deep dive shows. A major problem: access to medical care.
The short answer: we're not financially prepared for a slowly aging, healthy population, according to a recently published analysis.
Approvals and reviews continue—for now—despite government shutdown.
A roundup of some exchange-related news circling the web.
Growing client demand encouraged the agency to make its HCP content capabilities official.
The midnight shutdown put 800,000 government employees on leave, including those at the FDA, NIH and CDC.
Congress continues to war over healthcare reform. Exchanges will be able to take on members even if the government closes up shop.
Sanofi's PCSK9 agent receives high praise from analysts, Consumer Reports analyzes healthcare reform, Congressional committees propose compounding legislation, NIH funds genomic research.
Despite a possible government standoff, exchanges are coming, as is a proffered rebrand; Amgen signs a university deal in China; Pakistan seeks to rein in pharma; digital marketing is on the rise, research shows
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
Sanofi has to provide more Aubagio data to the UK's NICE; healthcare reform's sixes and sevens; NIH puts money toward Alzheimer's research
Biogen extend Isis relationship for six years and $100M; HHS readies healthcare reform TV push; Medivir ends hep. B clinical trial; FDA approves Celgene cancer drug; Baxter seeks Enbrel biosimilar
Benefits research studies show employers expect to lay out 7% more in healthcare costs in 2014, a move that has not been accompanied by lower employee costs.
Takeda moves an Alzheimer's treatment to Phase III; Sangamo acquires Ceregene; Catalyst gets breakthrough designation for auto-immune disorder drug; study says seniors likely to opt out of health insurance
Eli Lilly is accused of misconduct in China, Health and Human Services tries to get young adults interested in health insurance, Novo kid-friendly insulin pen approved; India biotech says its Herceptin biosimilar will launch this year.
Allergan asks FDA to reconsider Restatis generics requirements, Incyte's Jakafi could be pancreatic cancer nemesis, Medtronic says its strategy is at the heart of where healthcare is going and Aetna's app alliance makes health local and personal.
Abbott's Depakote lawsuits roll on; IMS buys mobile health firm's assets; BI shutters a chemical plant; and the healthcare reform back-and-forth continues.
Eisai lobbies to push back Belviq's patent clock; a case against Paula Deen is dismissed; Merck and Avanir team up to promote Januvia; and another healthcare-reform measure is pushed back
The healthcare reform information campaign continues; J&J settles a shareholder lawsuit; Eli Lilly freezes company salaries; and Quest dumps cancer med royalty rights.
The White House released its proposed budget for the 2014 fiscal year this morning, and while it gives a modest boost to Health and Human Services, it also seeks to extract more cost savings from pharmas.
President Obama has cemented his greatest legislative achievement, the Affordable Care Act, but the status quo should prove anything but boring, with implementation of the law sure to mean more political fireworks
Barack Obama edged Mitt Romney in fundraising from pharmas in the 2012 election, even as the industry favored Republicans in other contests. Were change-weary drug companies voting for the status quo?
Solo practitioners favor Mitt Romney over Barack Obama by a two-to-one ratio, a survey finds, suggesting that changes in reimbursement driven by Obamacare are driving physicians' presidential preferences.